SCHEMBL4137137

SCHEMBL4137137

O=c1ccc2ncc(Cl)cc2[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F11 P03951 1/20 0.47
HCAR1 Q9BXC0 4/20 0.44
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
PABPC1 P11940 1/20 0.43
KMT2A Q03164 1/20 0.43
MAPKAPK2 P49137 1/20 0.43
RPS6KA3 P51812 1/20 0.43
CSNK2A1 P68400 1/20 0.43
PLK3 Q9H4B4 1/20 0.43
ALDH1A1 P00352 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
HPGD P15428 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
HTR3E A5X5Y0 1/20 0.42
HTR3B O95264 1/20 0.42
HTR3A P46098 1/20 0.42
BACE1 P56817 1/20 0.42
HTR3D Q70Z44 1/20 0.42
HTR3C Q8WXA8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31093789 1.00 F11 (0.47) F11HCAR1MEN1LMNAPABPC1
SCHEMBL9228663 0.87 MAPKAPK2 (0.50) F11MEN1LMNAKMT2AMAPKAPK2
SCHEMBL30637065 0.87 MAPKAPK2 (0.50) F11MEN1LMNAKMT2AMAPKAPK2
SCHEMBL4135331 0.79 CA12 (0.46) HCAR1KMT2AMAPKAPK2RPS6KA3CSNK2A1
SCHEMBL9980482 0.79 MAPKAPK2 (0.42) F11HCAR1MAPKAPK2RPS6KA3CSNK2A1
SCHEMBL4135759 0.79 DYRK1A (0.49) HCAR1LMNAMAPKAPK2RPS6KA3CSNK2A1
SCHEMBL1378724 0.79 MAPKAPK2 (0.42) HCAR1MAPKAPK2RPS6KA3CSNK2A1PLK3
SCHEMBL8874223 0.77 GRIN2D (0.52) MEN1KMT2AALDH1A1SMN1; SMN2HPGD
SCHEMBL1374700 0.75 MMP12 (0.47) HCAR1ALDH1A1SMN1; SMN2HPGDPDE3B
SCHEMBL30011367 0.75 MAPKAPK2 (0.39) F11HCAR1MAPKAPK2RPS6KA3CSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9493459-B2 Azetidine and piperidine compounds useful as PDE10 inhibitors AMGEN INC. (US) 2016-11-15 US disclosed
US-20160176874-A1 AZETIDINE AND PIPERIDINE COMPOUNDS USEFUL AS PDE10 INHIBITORS AMGEN INC. 2016-06-23 US disclosed
US-9303028-B2 Azetidine and piperidine compounds useful as PDE10 inhibitors AMGEN INC. (US) 2016-04-05 US disclosed
EP-2864317-A1 AZETIDINE AND PIPERIDINE COMPOUNDS USEFUL AS PDE10 INHIBITORS AMGEN, INC. (US) 2015-04-29 EP disclosed
US-20140243302-A1 BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS MERCK SHARP & DOHME CORPORATION (US) 2014-08-28 US disclosed
EP-2022793-B1 NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF TOYAMA CHEMICAL CO LTD (JP) 2014-06-04 EP disclosed
EP-2022793-B1 NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF TOYAMA CHEMICAL CO LTD (JP) 2014-06-04 EP disclosed
US-20140148435-A1 AZETIDINE AND PIPERIDINE COMPOUNDS USEFUL AS PDE10 INHIBITORS AMGEN INC. (US) 2014-05-29 US disclosed
WO-2013188724-A1 AZETIDINE AND PIPERIDINE COMPOUNDS USEFUL AS PDE10 INHIBITORS AMGEN INC. (US) 2013-12-19 WO disclosed
US-20130338138-A1 AZETIDINE AND PIPERIDINE COMPOUNDS USEFUL AS PDE10 INHIBITORS AMGEN INC. 2013-12-19 US disclosed
US-20120226035-A1 NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-09-06 US disclosed
US-20120226035-A1 NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-09-06 US disclosed
US-8211908-B2 Heterocyclic compound or salt thereof and intermediate thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-07-03 US disclosed
US-8211908-B2 Heterocyclic compound or salt thereof and intermediate thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-07-03 US disclosed
US-8211908-B2 Heterocyclic compound or salt thereof and intermediate thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-07-03 US disclosed
US-20090198063-A1 NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-08-06 US disclosed
US-20090198063-A1 NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-08-06 US disclosed
US-20090198063-A1 NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-08-06 US disclosed
EP-2022793-A1 NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-02-11 EP disclosed
EP-2022793-A1 NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-02-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160176874-A1 AZETIDINE AND PIPERIDINE COMPOUNDS USEFUL AS PDE10 INHIBITORS PDE10A, PDE9A, PDE2A F11 4701/4885HCAR1 2143/4885MEN1 2881/4885
US-20140243302-A1 BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS PAICS, SBDS, SORD F11 4189/4885HCAR1 681/4885MEN1 3154/4885
US-20140148435-A1 AZETIDINE AND PIPERIDINE COMPOUNDS USEFUL AS PDE10 INHIBITORS PDE10A, PDE9A, PDE2A F11 4701/4885HCAR1 2143/4885MEN1 2881/4885
US-20130338138-A1 AZETIDINE AND PIPERIDINE COMPOUNDS USEFUL AS PDE10 INHIBITORS PDE10A, PDE9A, PDE2A F11 4701/4885HCAR1 2143/4885MEN1 2881/4885
US-20090198063-A1 NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF IKZF3, ZC3HAV1L, H1-4 F11 473/4885HCAR1 1208/4885MEN1 1840/4885
US-20120226035-A1 NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF IKZF3, ZC3HAV1L, CXXC5 F11 377/4885HCAR1 1360/4885MEN1 1844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.